ReviewThe oncologist2025

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.

B J Rimel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.